Transpek Industry Q1 FY27 Share Price & Earnings Call Analysis

₹1,292.60+2.29% today
Market cap
₹716 Cr
P/E
18.35
ROE
6.14%
PEG
-1.00
Price to sales
1.16
Debt to equity
0.10
52W high / low
₹1,446 / ₹5.63
Sales growth (5Y)
12.85%
EBITDA margin
14.48%
Net profit margin
7.48%
Promoter holding
57.28%
Sales (last year)
₹618 Cr

Incorporated in 1965, Transpek Industry Ltd manufactures and exports a range of chemicals[1]

Guidance scorecard · Q1 FY27 call

What Transpek Industry's management guided
and where it ranks in Chemicals & Petrochemicals

#65of 70 in
Chemicals & Petrochemicals

RevenueQ1 FY27 call

10–20%
  • Transpek Industry Limited expects a revenue growth of 15% to 20% for the current financial year (FY27) compared to the previous year.
  • Growth is driven by volume plus value increase, with some products like acid chlorides already showing higher revenue (INR4 crores last year to an expected INR15 crores this year).
  • The company plans to double its size and business in the next 5 years based on finalized strategies focusing on core product profiles and applications.
  • New product commercialization is anticipated with two products expected to bring around INR50 crores each annually once fully commercialized.
  • Some capex is planned ahead of confirmed demand based on market studies and customer relationships to support growth.

2 more points from Transpek Industry's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Transpek Industry said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Planned capex of around INR 250 crores over 5-6 years, phased.
  • Odisha greenfield project: Board approval sought within 25-30 days; feasibility study filing and government presentations expected by Sept-Nov 2026.
  • Project timelines: 3-4 months for permissions post-approval, with 1-2 years for construction and commercial production.
  • Multi-purpose pilot plant at Ekalbara (not Odisha) to scale-up products from kilo-lab to tonnage, expected operational by Feb 2027.
  • Continued investment in new product development; aiming for commercialization of several products generating INR 50-100 crores annually.
  • Past capex (~INR 200 crores last 5-6 years) largely maintenance and captive consumption expansions, not growth-focused.

2 more points from Transpek Industry's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Transpek Industry said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • Bimal Mehta highlights that some customers are currently working with Transpek, providing clear visibility of demand for certain products.
  • Discussions with customers for new contracts, including sizeable contracts similar to DuPont, are ongoing but delayed due to market volatility and cautious decision-making.
  • Transpek has shifted from a very conservative capex approach to investing ahead of confirmed demand based on market studies and customer relationships.
  • New products are under development, with expected revenue streams emerging by the end of the current financial year and the next year.
Full Q1 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. Strong growth
    3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Chemicals & Petrochemicals companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹1,878 Cr21.0
240%+Up 0–2%₹243 Cr3.1
340%+Flat₹7,887 Cr195.1
440%+Flat₹3,292 Cr4.3
540%+Flat₹2,311 Cr26.4
640%+Flat₹180 Cr11.8

Sign up free to see every company in the sector ranking and track Transpek Industry.

Pro shows every company guiding 40%+ revenue growth →Full Chemicals & Petrochemicals ranking

Financials of Transpek Industry

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Transpek Industry

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +202.76162.16120.94148.32148.21151.86162.70170.04165.26154.23160.27158.48148.22
Expenses +162.62139.65107.58120.64129.44135.84140.18146.10133.05130.18133.59133.55130.49
Operating Profit40.1422.5113.3627.6818.7716.0222.5223.9432.2124.0526.6824.9317.73
OPM %19.80%13.88%11.05%18.66%12.66%10.55%13.84%14.08%19.49%15.59%16.65%15.73%11.96%
Other Income +5.2911.674.074.634.7910.985.094.897.7411.665.033.544.27
Interest5.794.153.043.693.493.012.823.122.792.462.411.671.52
Depreciation8.498.788.838.6611.3312.3212.8912.1312.6412.3212.3412.3411.64
Profit before tax31.1521.255.5619.968.7411.6711.9013.5824.5220.9316.9614.468.84
Tax %28.19%25.41%46.22%29.46%35.47%20.31%19.66%21.58%21.49%25.56%25.53%25.03%25.45%
Net Profit +22.3715.852.9914.085.649.299.5510.6519.2515.5812.6410.856.58
EPS in Rs40.0528.385.3525.2110.1016.6317.1019.0734.4627.8922.6319.4211.78

Financials of Transpek Industry

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +290284317361595566339599827580650621
Expenses +251236263314478447292499676497547528
Operating Profit38485347117118471001518210393
OPM %13%17%17%13%20%21%14%17%18%14%16%15%
Other Income +1127101817172414252024
Interest1311912191610111914128
Depreciation989101426293033385049
Profit before tax27324235101942684113566261
Tax %18%33%29%25%35%22%9%22%26%31%21%25%
Net Profit +222130266673236583394946
EPS in Rs37.4136.2453.6747.26117.70130.5941.73117.09149.4669.0387.2681.73
Dividend Payout %13%21%17%19%17%10%18%19%18%20%23%24%

Financials of Transpek Industry

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital666666666666
Reserves6985200241306333374479581668740762
Borrowings +7764882031441161111371451239460
Other Liabilities +775593116143134109143155169161181
Total Liabilities2292093865665995895997648879661,0011,008
Fixed Assets +9294117179236287287295365397360343
CWIP51013563319141624655
Investments55131144149118142196238321328316
Other Assets +126100125188180166156258260242307344
Total Assets2292093865665995895997648879661,0011,008

Financials of Transpek Industry

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1944477128111354711198135
Cash from Investing Activity +14-16-31-103-45-33-17-70-13-32-30
Cash from Financing Activity +-33-27-1796-83-77-39-94-64-56
Net Cash Flow-01-10-0015-144348
Free Cash Flow242710-11280742096660116
CFO/OP52%103%106%38%126%114%81%70%97%133%140%

Financials of Transpek Industry

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1035978945758826052585888
Inventory Days6811191876870827754827463
Days Payable11460831037273816545587087
Cash Conversion Cycle5711085785454837261816164
Working Capital Days112210-81160271732444452
ROCE %22%28%23%13%27%24%7%18%20%9%10%8%

Guidance history

How Transpek Industry's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlanned——
Q3 FY25 call →0–10%FlatPlanned——
Q4 FY24 call →10–20%FlatNone plannedNone planned—
Q3 FY23 call →20–40%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

29out of 100

Momentum score · price trend

29 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,928 stocks
Last 12 months−8.7%45%
Last 6 months+7.2%62%
Last 3 months+4.9%73%

The price is 47% below its all-time high of ₹2,440.3 (4 Nov 2021). Stocks more than 20% below their peak have their score halved, so 57 became 29.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,928 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Transpek Industry: 0.4 × 45 + 0.4 × 62 + 0.2 × 73 = 57, halved to 29 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 9 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Others in Chemicals & Petrochemicals this season

  • Unilex Colour &C (Q2 FY27)

    685.02 lakhs (Consolidated) with a YoY increase of approximately 2.22% (Rs. Key results statement takeaways from Unilex Colour & Chemical Ltd's Q2 FY27 results

  • Andhra Sugars (Q2 FY27)

    3,276.52 lakhs (~5.5% increase) . Key results statement takeaways from Andhra Sugars Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Shanti Inorganics (Q2 FY27)

    54.02 crore (Rs. Key results statement takeaways from Shanti Inorganics Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Prolife Industries (Q2 FY27)

    Year-on-Year Change for PAT**: Specific YoY % change not provided; previous period PAT for the half year ended Sept 30, 2025 is not provided in the shared…